Why the study?
What are the clinical outcomes of Impella support in patients with cardiogenic shock or undergoing high-risk PCI?
What are the clinical outcomes of Impella support in patients with cardiogenic shock or undergoing high-risk PCI?
In a single-center experience, Impella support for high-risk PCI yielded outcomes comparable to existing literature, but its use in cardiogenic shock remained associated with high mortality and complications.
Answers are grounded in this paper and cite their sources.
High mortality with Impella in cardiogenic shock warrants careful selection; leaves open randomized trials to define benefit in observational cohorts.
The short- and long-term results of Impella®-supported HR-PCI were comparable to those in the literature. In the CS group, in-hospital and short-term outcomes were poor, with high mortality and non-negligible complication rates.
No takes yet. Share an insight, caveat, or question.
Brandao et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: